Niacin news from FierceBiotech
News
Analyst predicts a long delay for Merck's Cordaptive
There's more bad news--or analysis--for Merck's drug development efforts. After the FDA Read more...
Merck shares hammered after FDA rejects Cordaptive
Shares of Merck were sliding again this morning on the news that the FDA has turned thumbs down on MK-0524A, its new cholesterol therapy. The stock dropped eight percent after regulators announced Read more...
Merck scores high in race for cholesterol drug
Merck is reporting success in its Phase III trial of a new cholesterol drug that combines a known ingredient with a new one that reduces the risk of an uncomfortable and common side effect. Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends